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during the last month of treatment. RESULTS: Of 167 patients
(20 men, 147 women; mean age 43.5 years) included in the
analysis, 72% responded to tegaserod. At baseline, SF-36 scores
from IBS-C patients were lower than those from the general pop-
ulation, but increased in all dimensions with treatment (p =
0.0068 for General Health), reaching values similar to those of
the general population. An increase in all SF-36 dimensions was
observed in responders (R), whereas a decrease occurred in non-
responders (NR, General Health dimension p = 0.004). IBS-QOL
scores (from baseline to treatment) signiﬁcantly increased in all
dimensions (p < 0.0001 for overall assessment). The mean incre-
ment in IBS-QOL was greater for R than NR (Overall dimen-
sion, p < 0.05). Upon treatment withdrawal, some dimensions
of SF-36 and IBS-QOL scores decreased but did not return to
pretreatment levels. CONCLUSIONS: QoL is impaired in IBS-C
patients. Treatment with tegaserod 6mg b.i.d. improves QoL in
patients with IBS-C to a level almost equivalent to that of the
general population, and deterioration in QoL occurs upon treat-
ment discontinuation.
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OBJECTIVE: To assess completeness of safety reporting in pub-
lished clinical trials, including use of incidence, severity, and rela-
tionship to drug thresholds for listing of speciﬁc adverse events
(AEs). METHODS: We used data from previously conducted
systematic reviews in three areas: treatment of rheumatoid
arthritis (RA) with disease-modifying anti-rheumatic drugs (168
studies, 1969–2001); treatment of migraine with 5HT-1 agonists
(38 studies, 1991–2003); and anti-neoplastic treatment of
relapsed or refractory non-Hodgkin’s lymphoma (NHL) (27
studies, 1991–2003). The type of safety reporting for each study
was appraised by two reviewers. RESULTS: Only a minority of
studies in each of the clinical areas presented a complete listing
of all AEs occuring during the trial (RA 17%, migraine 8%,
NHL 30%); a substantial number (10–25%) had no safety data
extractable. Among studies with partial AE reporting the thresh-
olds used varied by clinical setting: two-thirds of RA and NHL
studies with a reporting threshold used the author- or investiga-
tor-attributed relationship to drug to determine which AEs
would be listed in published reports, while 71% of migraine
studies with a threshold used incidence (e.g. only AEs occuring
in more than 5% of patients were listed). The severity threshold
(reporting of only serious AEs or only grade 3–4 AEs) was the
least common in all three clinical areas examined. No consistent
relationship was found between complete AE reporting and
study sponsorship (industry vs. non-industry/not reported) or
year published (pre vs. post 1995). Smaller studies (<100
patients) were more likely to contain complete AE reporting,
perhaps due to the difﬁculty of providing a comprehensive listing
of all events in larger studies. CONCLUSIONS: Incidence and
relationship to drug remain common thresholds for AE report-
ing in published clinical trials. Early detection of rare or unan-
ticipated events by meta-analysis of published trial data is thus
made more challenging.
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Genetic test technologies offer hope for early diagnosis and iden-
tiﬁcation of persons at risk for serious diseases. Because many of
these tests are costly and applicable to large populations, evalu-
ations of the cost-effectiveness of these technologies are impor-
tant. OBJECTIVES: To conduct a systematic search for and
review of economic evaluations of genetic testing technologies.
METHODS: PubMed, Proquest, LexisNexis, Expanded 
Academic Index, The Harvard Review of Economic Analyses,
PsyclINFO, NICE and CCOHTA databases were searched for
original cost-effectiveness articles published from 1990 to
present. MESH terms included: economic(s) and/or cost(s),
genetic, gene, and/or genotype. Selection criteria included genetic
tests for genetic conditions, deﬁned as analysis of human DNA,
RNA, chromosomes, proteins, and certain metabolites in order
to detect heritable disease-related genotypes, mutations, pheno-
types or karyotypes for clinical purposes. Articles were catego-
rized by clinical category and type of economic study (e.g.,
cost-utility, cost-beneﬁt), then graded independently by the
authors using CEA study quality system developed by Chiou et
al (Med Care, 2003;41:32). RESULTS: A total of 149 abstracts
were retrieved using the search terms; 63 met selection criteria.
Types of economic studies were as follows, cost-utility (25%);
cost-beneﬁt (19%); cost-minimization (6%); cost-effectiveness
(59%). Clinical testing categories were as follows: preconception
carrier (8%); prenatal diagnosis (40%); adult (57%). The studies
involved 26 different medical conditions. Study quality ranged
from 43–100 (average 82). Cost-utility studies were of highest
quality (mean 91); cost-minimization studies were of lowest
quality (mean 63). Adult studies had the highest rating (mean
86); preconception testing studies were lowest in quality (mean
74). Intraclass correlation among raters was 0.82 (CI 0.70–0.89).
CONCLUSIONS: A number of economic analyses have been
published in human genetics across a wide range of conditions.
Study quality varied widely. Priority areas for the ﬁeld include
increasing quality and uniformity of measures of outcome.
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OBJECTIVES: The purpose of this study was to evaluate the
effects of using Duan’s mean anti-logged residuals (mean smear-
ing estimator) or a median smearing estimator with positively
skewed distributions on predicting costs. METHODS: Data for
this study came from managed care pharmacy and medical
records containing drug-drug interactions (DDIs) from January
1, 1997 to December 31, 1999. Two matched cohort groups
were studied. DDI cases were identiﬁed as receiving medications
involving monoamine oxidase inhibitor (MAOIs) or anti-
coagulant DDIs. Controls were age and sex matched to cases.
Costs were positively skewed and were then natural log trans-
formed as the dependent variable in regression models. The
retransformed costs employing the mean and median smearing
estimators, respectively, were compared. Model ﬁt was assessed
using mean squared error (MSE) for both mean and median
smearing estimators. RESULTS: A total of 156 and 5754 sub-
jects were identiﬁed as MAOI and anti-coagulant groups, respec-
